Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
ARDX.US
id: 1317
Ardelyx (ARDX) Drug Prospects Case
D. Massachusetts
Court1:24-cv-12119
Case number10/31/2023
Class period Start07/01/2024
Class period End10/15/2024
Lead Plaintiff motion deadline- $ARDX stockholders filed a claim against Ardelyx for misleading them about the prospects and success of its drug.
- After the news on July 2, 2024, $ARDX dropped by over 30%.
- Ardelyx investors can join this case to be notified about potential recovery.
Case Details:
Ardelyx's drug (XPHOZAH) got FDA approval on October 17, 2023, to help dialysis patients with high phosphorus levels.
Ardelyx had previously announced plans to apply for XPHOZAH to be included in TDAPA and confirmed this intent during a May 2024 earnings call.
However, on July 2, 2024, they unexpectedly revealed they would not be making the application.
On this news, $ARDX fell by 30.25% on the same day.
Considering all the representations, investors suspect Ardelyx misled them about the prospects and success of its drug.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Mismanagement,
Misleading Statements,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07/02/2024
Filing date
08/16/2024
Lead Plaintiff Deadline
10/15/2024